Insights On CONTRACT PHARMA MANUFACTURING

  1. CHO Cell Lines For Recombinant Protein Production 6/2/2025

    Discover how new strategies in CHO cell line development are driving innovation and transforming the future of biologics manufacturing, from enhanced productivity to improved therapeutic quality.

  2. Leading European CDMO For Drug Product Manufacturing 6/2/2025

    As timelines tighten and regulatory demands grow, discover how a European CDMO delivers integrated solutions from aseptic fill and finish to packaging and release.

  3. Establishing A Versatile Platform For Intensified Lentiviral Vector Manufacturing 6/2/2025

    Accelerate access to high-quality, cost-effective lentiviral vectors with our intensified TFDF-based manufacturing platform, delivering multi-fold yield improvements and scalable, space-efficient production.

  4. Optimizing AAV8 Capsid Purification With Oversized GOI 6/2/2025

    Enhance AAV gene therapy quality and regulatory compliance with our advanced AEX-based purification platform, achieving >90% full capsid purity — even for oversized AAV8 vectors.

  5. Optimization Of rAAV Production Using An In-House Suspension HEK293 Cell Line 6/2/2025

    Boost rAAV yields and quality while reducing costs with our proprietary HEK293 cell line and scalable, optimized manufacturing platform for gene therapy.

  6. Engineering Rep-Cap Plasmids To Enhance AAV Manufacturability, Potency 6/2/2025

    Discover how our engineered Rep-Cap plasmids dramatically enhance AAV vector yield, quality, and scalability, offering a powerful, next-generation solution to overcome manufacturing challenges.

  7. Streamlining Development: Advantages Of An All-In-One Solution 6/2/2025

    Antibody-drug conjugate (ADC) development requires tightly integrated manufacturing. Streamlined, end-to-end solutions reduce complexity, improve quality, and accelerate time-to-market.

  8. Leveraging Robust Immunogenicity Assessments To Mitigate Clinical Risks 6/2/2025

    By improving the granularity and interpretability of preclinical immunogenicity data, EpiScreen® 2.0 supports more confident lead selection and helps mitigate downstream clinical risks.

  9. Advancements In Evaluating Fc-Mediated Functional Activity In Biologics 6/2/2025

    Watch this presentation to gain a comprehensive overview of how to evaluate Fc-mediated functions — and why doing so is vital to the success of biologic therapies.

  10. Timing Is Everything: Choosing The Right Bioassay To Increase Success 6/2/2025

    Discover how phase-appropriate bioassays deliver regulatory-compliant, decision-ready data — from early discovery to commercial production.